Top in allergy/asthma: ‘Psychosocial burden’ of food allergy; peanut allergy patch
Regardless of sociodemographic or clinical characteristics, children with food allergy face a significant psychosocial burden, according to a survey of caregivers published in The Journal of Allergy and Clinical Immunology: In Practice.
More than 4,000 caregivers from households in the U.S. completed the FAIM, for which higher scores from one to seven equaled greater psychological burden. Researchers found that mean FAIM score for children with reported food allergy was 2.79, which increased to 2.96 for children with convincing food allergy and 3.21 for children with physician-confirmed convincing food allergy.
“By quickly screening patients at regular intervals, doctors can identify patients experiencing increased psychosocial burden and subsequently provide/connect families with prevention or intervention efforts to decrease food allergy-related psychosocial burden and enhance health-related quality of life,” Melissa L. Engel, PhD, postdoctoral fellow with the Center for Food Allergy and Asthma Research (CFAAR) at Feinberg School of Medicine, told Healio.
It was the top story in allergy/asthma last week.
In another top story, the VIASKIN Peanut patch allowed two-thirds of toddlers with a peanut allergy to successfully complete an oral food challenge at 3 years without meeting stopping criteria.
Read these and more top stories in allergy/asthma below:
Children with food allergy face ‘substantial’ psychosocial burden
Children with food allergy face a substantial psychosocial burden regardless of their sociodemographic or clinical characteristics, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Patch effective through 36 months in treating toddlers with peanut allergy
Two-thirds of toddlers with peanut allergy who used the VIASKIN Peanut patch from DBV Technologies completed an oral food challenge at 36 months without meeting criteria for stopping, according to a webinar held by the company. Read more.
FDA issues anaphylaxis warning on multiple sclerosis treatment
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is associated with a risk for anaphylaxis and issued a new boxed warning, according to a drug safety communication. Read more.
Global pediatric atopic dermatitis increased over 6% from 2000 to 2021
While pediatric atopic dermatitis cases rose globally between 2000 and 2021, the prevalence rate dropped, showing important global patterns, study results published in Annals of Allergy, Asthma & Immunology showed. Read more.
Daily caffeine intake during pregnancy lowers risk for asthma in children
High maternal daily caffeine intake led to a lower risk for asthma in children, according to study results. Read more.